Literature DB >> 3608888

The effects of preterm delivery and mechanical ventilation on human lung growth.

A A Hislop, J S Wigglesworth, R Desai, V Aber.   

Abstract

The effects of preterm birth and mechanical ventilation on growth of the alveolar region of the lung were assessed by morphometric and/or quantitative biochemical methods in the lungs from 104 perinatal and infant autopsies. The lungs of 4 preterm infants who died at 4-16 weeks age without having received mechanical ventilation were large relative to body weight but showed normal alveolar number and alveolar surface area. Infants treated by mechanical ventilation for hyaline membrane disease (HMD) and who died at ages from 1 week up to 14 months showed impairment in alveolar development evidenced by low alveolar number and a low alveolar surface area. Lung volume and total lung DNA values were relatively normal. Dilated alveolar ducts were a feature at all ages with emphysematous changes apparent in the longest surviving infants. Biochemical features included a high concentration of hydroxyproline, reflecting collagen, and a high desmosine concentration, reflecting elastin, in infants dying at less than 60 weeks postconceptional age. Changes in the lungs of infants ventilated at low pressures for conditions other than HMD were of a similar nature but less severe than those seen in the HMD group. These findings indicate that preterm birth alone may have little adverse influence on lung development but that conditions necessitating mechanical ventilation may lead to permanent impairment in alveolar development. We postulate that the standard technique of applying positive pressure ventilation may itself lead to impaired alveolar growth, although the effect is enhanced by concomitant HMD and BPD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3608888     DOI: 10.1016/0378-3782(87)90003-x

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  38 in total

Review 1.  Long term sequelae of bronchopulmonary dysplasia (chronic lung disease of infancy).

Authors:  E Eber; M S Zach
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

2.  Changes in pulmonary arterial pressure in preterm infants with chronic lung disease.

Authors:  N V Subhedar; N J Shaw
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

Review 3.  Lung growth: implications for the newborn infant.

Authors:  S Kotecha
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-01       Impact factor: 5.747

Review 4.  Airway and blood vessel interaction during lung development.

Authors:  Alison A Hislop
Journal:  J Anat       Date:  2002-10       Impact factor: 2.610

5.  Assessment of pulmonary function in resolving chronic lung disease of prematurity.

Authors:  R Iles; A T Edmunds
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-03       Impact factor: 5.747

6.  Lung function in children of low birth weight.

Authors:  K N Chan; C M Noble-Jamieson; A Elliman; E M Bryan; M Silverman
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

Review 7.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 8.  Effects of antenatal and postnatal corticosteroids on the preterm lung.

Authors:  J Vyas; S Kotecha
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

9.  Catch-up alveolarization in ex-preterm children: evidence from (3)He magnetic resonance.

Authors:  Manjith Narayanan; Caroline S Beardsmore; John Owers-Bradley; Cristian M Dogaru; Marius Mada; Iain Ball; Ruslan R Garipov; Claudia E Kuehni; Ben D Spycher; Michael Silverman
Journal:  Am J Respir Crit Care Med       Date:  2013-05-15       Impact factor: 21.405

10.  Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies.

Authors:  Carl T D'Angio; William M Maniscalco
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.